Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Prostatic Neoplasms 2Waldenstrom Macroglobulinemia 1Stomatitis 1Leukemia 1Head and Neck Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 519Specimen Handling 382Carboplatin 374Magnetic Resonance Spectroscopy 337Cisplatin 328Nivolumab 309Cyclophosphamide 296Radiotherapy 256Paclitaxel 256Gemcitabine 235Biopsy 234Bevacizumab 213Dexamethasone 169durvalumab 166Oxaliplatin 162Rituximab 158Capecitabine 157Fluorouracil 148venetoclax 147Docetaxel 146Etoposide 141atezolizumab 140Drug Therapy 140Doxorubicin 134Ipilimumab 130Prednisone 120Lenalidomide 119Radiosurgery 118Leucovorin 112fludarabine 108

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Valacyclovir × 1 year × Clear all
NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT07363031 2026-01-23

Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy

Instituto Oncoclinicas

Phase 2 Enrolling by invitation
84 enrolled
Head & Neck

Head and Neck Neoplasms, Stomatitis

NCT02768363 2025-07-30

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

Phase 2 Active not recruiting
187 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡